Sutro Biopharma Past Earnings Performance
Past criteria checks 0/6
Sutro Biopharma's earnings have been declining at an average annual rate of -25.6%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 28.8% per year.
Key information
-25.6%
Earnings growth rate
-7.5%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 28.8% |
| Return on equity | -111.4% |
| Net Margin | -77.0% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Sutro Biopharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 161 | -124 | 56 | 0 |
| 30 Jun 24 | 169 | -124 | 57 | 0 |
| 31 Mar 24 | 154 | -115 | 60 | 0 |
| 31 Dec 23 | 154 | -107 | 63 | 0 |
| 30 Sep 23 | 49 | -172 | 60 | 0 |
| 30 Jun 23 | 57 | -143 | 60 | 0 |
| 31 Mar 23 | 75 | -130 | 60 | 0 |
| 31 Dec 22 | 68 | -119 | 60 | 0 |
| 30 Sep 22 | 70 | -123 | 61 | 0 |
| 30 Jun 22 | 53 | -134 | 63 | 0 |
| 31 Mar 22 | 53 | -114 | 60 | 0 |
| 31 Dec 21 | 62 | -106 | 56 | 0 |
| 30 Sep 21 | 60 | -127 | 48 | 0 |
| 30 Jun 21 | 69 | -79 | 41 | 0 |
| 31 Mar 21 | 50 | -43 | 39 | 0 |
| 31 Dec 20 | 43 | -32 | 37 | 0 |
| 30 Sep 20 | 46 | 13 | 38 | 0 |
| 30 Jun 20 | 40 | -17 | 36 | 0 |
| 31 Mar 20 | 41 | -61 | 34 | 0 |
| 31 Dec 19 | 43 | -56 | 33 | 0 |
| 30 Sep 19 | 51 | -42 | 32 | 0 |
| 30 Jun 19 | 46 | -40 | 29 | 0 |
| 31 Mar 19 | 41 | -38 | 25 | 0 |
| 31 Dec 18 | 38 | -35 | 22 | 0 |
| 30 Sep 18 | 23 | -49 | 18 | 0 |
| 30 Jun 18 | 33 | -40 | 18 | 0 |
| 31 Mar 18 | 42 | -30 | 17 | 0 |
| 31 Dec 17 | 52 | -20 | 16 | 0 |
| 31 Dec 16 | 60 | 0 | 15 | 0 |
Quality Earnings: S09 is currently unprofitable.
Growing Profit Margin: S09 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: S09 is unprofitable, and losses have increased over the past 5 years at a rate of 25.6% per year.
Accelerating Growth: Unable to compare S09's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: S09 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: S09 has a negative Return on Equity (-111.45%), as it is currently unprofitable.